Preliminary data from two expansion cohorts of the phase 1 trial, in which anti-PD-1/PD-L1-naive and experienced patients with advanced melanoma were treated with fianlimab in combination with cemiplimab showed encouraging antitumor activity with an ORR of 63.8% for anti-PD-1/PD-L1-naive and 13.3% for anti-PD-1/PD-L1-experienced patients. Here, PDCD1 is linked to melanoma.